A candidate PPARγ to GPX4 axis in ferroptosis suppression and platinum resistance in bladder cancer: evidence appraisal and a testable research agenda.

Abstract

Cytotoxic chemotherapy no longer holds an uncontested place in the treatment of muscle-invasive bladder cancer, although platinum-based therapy remains relevant in selected perioperative, bladder-preservation, upper-tract, and salvage settings. Mechanisms of platinum resistance therefore retain clinical importance. Ferroptosis, an iron-dependent form of regulated cell death constrained by glutathione peroxidase 4 (GPX4), has been implicated in treatment tolerance and drug-tolerant persister states. Here, we provide a narrative evidence appraisal of peroxisome proliferator-activated receptor gamma (PPARγ) as a candidate upstream regulator of GPX4-dependent ferroptosis resistance in bladder cancer. Two mechanistic arms are considered. The first proposes transcriptional regulation of GPX4 by PPARγ; however, positive regulation in bladder cancer is supported only by expression co-variation and in silico motif prediction, while evidence from another cellular context indicates that the direction of PPARγ-GPX4 regulation can be reversed. The second proposes that reduced SIRT1 activity could alter GPX4 acetylation and thereby influence its post-translational regulation. Although GPX4 acetylation has been directly demonstrated in non-urothelial systems, GPX4 has not been established as a SIRT1 substrate, and SIRT1-dependent control of GPX4 ubiquitination or turnover remains untested. We therefore present the PPARγ-GPX4 relationship as a context-dependent, testable hypothesis rather than an established "dual-lock" mechanism, and outline the experiments required to establish transcriptional directionality, post-translational regulation, ferroptosis dependence, and platinum sensitization in urothelial models.